Dr Zhang Ge wins the 2nd Class Award in National Science and Technology Progress for his joint research project on osteoporosis prevention


張戈博士的預防骨質疏鬆聯合研究項目獲國家教育部頒發科技進步獎(推廣類)二等獎

Date: 12 Jun 2014 (Thursday)

Archive

Dr Zhang Ge of School of Chinese Medicine wins 2nd Class Award in National Science and Technology Progress

中醫藥學院張戈博士獲國家教育部頒發科技進步獎 (推廣類) 二等獎

Dr Zhang Ge, Associate Director of the Teaching Division and Deputy Director of the Institute for Advancing Translational Medicine in Bone and Joint Diseases of the School of Chinese Medicine (SCM), won the 2nd Class Award in National Science and Technology Progress under the 2013 Higher Education Outstanding Scientific Research Output Awards (Science and Technology) conferred by the Ministry of Education for his contribution to a joint project entitled “Modernisation Research and Application of Anti-osteoporosis TCM Drugs”. 

The award-winning project, a collaborative project between Dr Zhang and his team together with his counterparts at The Chinese University of Hong Kong, The Hong Kong Polytechnic University and Jinan University, was the first multi-centre randomised clinical trial for anti-osteoporosis TCM herbs in the world. The result of the project has been published in the prestigious orthopaedic journal Journal of Bone and Miner Research.

Dr Zhang has been engaged in the selection of suitable TCM herbs for clinical trials for the purpose of developing novel anti-osteoporosis drugs from TCM herbs. As the Chinese medicinal plant Epimedium brevicornum maxim is rich in phytoestrogen flavonoids, Dr Zhang supervised a project on investigating the beneficial effects of Epimedium-derived phytoestrogen flavonoids (EPF) in the prevention of bone loss in postmenopausal women. A total of 100 women who have been undergoing menopause for 10 to 18 years were randomised into an EPF treatment group and a placebo control group for a 24-month clinical study. The results revealed that EPF had substantially decreased the loss of bone density in postmenopausal women in the treatment group. 

Dr Zhang said that osteoporosis is one of the common problems for postmenopausal women who are prone to accelerated bone loss due to the acute lowering of estrogen levels. He explained that since estrogen replacement therapy to prevent osteoporosis remains controversial, the HKBU research team is dedicated to developing new drugs from herbs and natural resources which, he believes, is a major trend for future drug discovery.

中醫藥學院教學部副主任兼骨與關節疾病轉化醫學研究所副所長張戈博士參與主理的一項題為「抗骨質疏鬆傳統中藥現代化研究及其應用」的聯合研究項目,早前榮獲國家教育部頒發2013年度「高等學校科學研究優秀成果獎(科學技術)」科技進步獎(推廣類)二等獎,表彰他在促進科學技術進步工作上的重大貢獻。

獲獎項目由張博士的團隊與香港中文大學、香港理工大學及暨南大學聯合進行,是國際上首個由多個研究中心對骨質疏鬆症聯合進行的中草藥臨床研究,研究結果已於骨科權威雜誌《Journal of Bone and Miner Research》上發表。

張博士的研究工作主要針對骨質疏鬆症等骨形成退化性疾病,篩選合適的中草藥進行臨床研究,旨在研發新型的抗骨質疏鬆藥。由於中草藥「淫羊藿」含有豐富的植物雌激素黃酮類化合物,張博士曾主理一項評價「淫羊藿總黃酮」預防絕經婦女於絕經後的骨質疏鬆症效能臨床研究。參與研究的100位婦女已絕經10至18年,她們隨機分為「治療組」和「安慰劑組」,進行為期24個月的臨床研究,結果顯示「淫羊藿總黃酮」治療有助預防「治療組」婦女骨密度下降,成效非常顯著。
   
張博士表示,一般婦女在絕經後會因為雌激素水平明顯下降而加速骨質流失,普遍會出現骨質疏鬆的問題。他指出,現時雌激素替代治療對預防骨質疏鬆症仍存在爭議,浸大研究團隊正積極從中草藥及天然資源中研發合適藥物,相信這個研究方向也是未來新藥研發的一大趨勢。